Dupont Nutrition Biosciences Aps

Nutrition & Biosciences USA 4, Inc.

International N&h Denmark Aps

E.i. Dupont De Nemours and Company

Dupont Industrial Biosciences Usa, LLC

Arthur Ouwehand

Robert DiCosimo

Qiong Cheng

Zheng You

Jian Ping Lai

Mark Scott Payne

Steven Cary Rothman

Kristin Ruebling-Jass

Nina Rautonen

Sampo Lahtinen

Kirsti Tiihonen

Sofia Forssten

Harri Mäkivuokko

Jaana Mättö

Zheyong Yu

Seppo Salminen

Zhenghong Zhang

Erika Isolauri

Gregory Leyer

Heli Putaala

Björn Andersch

Marta Korczynska

Wouter Herman Noordman

Heli Anglenius

Inger Mattsby-Baltzer

Janne Nikkilä

Marta Zdzislawa Korczynska

Seppo Jaakko Salminen

The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

Bacteria

The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.

An enzymatically produced soluble α-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble α-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble α-glucan fiber are also provided.

Enzymatic synthesis of soluble glucan fiber

An enzymatically produced soluble &#x3b1;-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble &#x3b1;-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble &#x3b1;-glucan fiber are also provided.

The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.

Probiotic bacteria for the topical treatment of skin disorders

The present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms.

Probiotics for use in relieving symptoms associated with gastronitestinal disorders

The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. Suitably, such compositions may compriseor both.

Probiotics for use in reducing eosinophilia and respiratory allergies

Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain ofspp. and/orspp., for example a strain ofand/or

[object Object]

Growing community of inventors

Inga, Finland

Arthur Ouwehand